Stay updated with breaking news from Outlayer Item. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has told Johnson & Johnson that more batches of COVID-19 vaccine produced at a plant under scrutiny for its manufacturing practices must be discarded. In a statement, the FDA said it determined “several” batches from the Emergent BioSolutions manufacturing facility in Baltimore “are not suitable for use.” It did not say how many doses of the country’s
Several researchers and global oncology leaders received ASCO’s Special Awards, the society’s highest honors.“The recipients of this year’s Special Awards have made exceptional contributions to the oncology community,” Monica Bertagnolli, MD, FACS, FASCO, past president of ASCO and chair of the Joint Special Awards Selection Committee, said in a society-issued press
Older individuals with intellectual and developmental disabilities were more likely to take more psychiatric medications and have more medical conditions, according to study results published in The American Journal of Geriatric Psychiatry. However, this patient population reported fewer psychiatric diagnoses.
ProDERM: High-dose IV immunoglobulin boosts treatment response in dermatomyositis Source: Disclosures: Aggarwal R. A randomized, double-blind, placebo-controlled phase III trial of IVIG 10% in patients with Dermatomyositis. The ProDERM study: Results on efficacy and safety. Presented at EULAR 2021 Congress; June 2-6, 2021 (virtual meeting).The researchers report study sponsorship from Octapharma. Aggarwal reports consulting fees from Q32, Alexion, Argenx, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Corbus, Csl Behring, EMD Serono, Janssen, Kezar, Mallinckrodt, Kyverna, Octaph...
Three phase 3 studies of brolucizumab in patients with retinal diseases will be terminated early after more frequent dosing intervals were associated with higher rates of intraocular inflammation, Novartis announced.The MERLIN study and the RAPTOR and RAVEN studies, whose methods all include periods of 4-week dosing intervals of Beovu (brolucizumab), will be stopped. And, “All other